NCT01318070View on ClinicalTrials.gov

Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

339

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Alogliptin and pioglitazone

Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.

DRUG

Alogliptin and pioglitazone

Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.

DRUG

Pioglitazone

Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY